Press Releases
Samsung Biologics Ranks No.1 in Pharmaceutical Brand Reputation List in Korea
Songdo, S. Korea, 09 March 2020 – Samsung Biologics (207940.KS), a world-class CMO, CDO, and CRO, announced that it took first place in the domestic brand reputation list, ranking among all pharmaceutical companies listed on the Korea stock exchange.
The Brand Reputation Index (BRI) is put together every month by the Korea Corporate Reputation Research Institute, based on its consumer activity-related big data analyses in multiple categories including Participation index, Communication index, Community index, and Market index.
Samsung Biologics was ranked first place in February with a BRI of 8,311,153, followed by Celltrion Healthcare in second, and Chong Kun Dang Pharmaceutical in third.
Since the company’s initial listing in 2016, Samsung Biologics has shown steady growth in its performance – revenue and profits have been climbing, debt ratio improved, and the yearly number of contracts signed jumped 30% for CMO and 740% for CDO from 2018 to 2019. Samsung Biologics has also been actively monitoring and communicating operational countermeasures amidst the recent COVID-19 crisis, working to address both client and public concerns.
Songdo, S. Korea, 09 March 2020 – Samsung Biologics (207940.KS), a world-class CMO, CDO, and CRO, announced that it took first place in the domestic brand reputation list, ranking among all pharmaceutical companies listed on the Korea stock exchange.
The Brand Reputation Index (BRI) is put together every month by the Korea Corporate Reputation Research Institute, based on its consumer activity-related big data analyses in multiple categories including Participation index, Communication index, Community index, and Market index.
Samsung Biologics was ranked first place in February with a BRI of 8,311,153, followed by Celltrion Healthcare in second, and Chong Kun Dang Pharmaceutical in third.
Since the company’s initial listing in 2016, Samsung Biologics has shown steady growth in its performance – revenue and profits have been climbing, debt ratio improved, and the yearly number of contracts signed jumped 30% for CMO and 740% for CDO from 2018 to 2019. Samsung Biologics has also been actively monitoring and communicating operational countermeasures amidst the recent COVID-19 crisis, working to address both client and public concerns.